Clinical Trial

Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of HSK39297 tablets in paroxysmal nocturnal hemoglobinuria (PNH) patients with anemia after stable treatment of anti-C5 antibody.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-29; most recent amendment 2026-02-09.
Status change: Recruiting → Completed 2026-02-09
Trial Details
NCT Number NCT07052838
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Paroxysmal Nocturnal Haemoglobinuria (PNH)
Enrollment 36 participants
Start Date 2025-05-12
Primary Completion 2025-12-23 (estimated)
Study Completion 2026-01-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-11